CSIMarket
 
Kiromic Biopharma Inc   (KRBP)
Other Ticker:  
 
 
Price: $1.0100 $-0.11 -9.821%
Day's High: $1.0425 Week Perf: -13.68 %
Day's Low: $ 1.01 30 Day Perf: -27.86 %
Volume (M): 0 52 Wk High: $ 3.78
Volume (M$): $ 0 52 Wk Avg: $1.92
Open: $1.04 52 Wk Low: $0.18



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 20
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Kiromic Biopharma Inc
Kiromic Biopharma Inc is a biotechnology company that specializes in developing innovative cell therapies for the treatment of various types of cancer. The company utilizes its proprietary technology platform to engineer immune cells and develop targeted therapies that can effectively destroy cancer cells while minimizing damage to healthy tissues.

Kiromic Biopharma Inc focuses on advancing personalized medicine and precision oncology by tailoring treatments to individual patient's genetic makeup. They utilize genomic data and advanced analytics to identify specific cancer targets and develop therapies that can directly address those targets.

The company's pipeline includes a range of cancer immunotherapies, including CAR-T cell therapies, T-cell receptor therapies, and immune checkpoint modulators. They are actively involved in preclinical and clinical trials to evaluate the safety and efficacy of their therapies.

Kiromic Biopharma Inc aims to provide patients with novel treatment options that have the potential to enhance survival rates and improve overall outcomes in cancer treatment. They collaborate with academic institutions, research organizations, and clinical partners to further advance their therapeutic approaches and bring their innovative treatments to the market.


   Company Address: 7707 Fannin Street, Suite 200 Houston 77054 TX
   Company Phone Number: 968-4888   Stock Exchange / Ticker: KRBP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BLUE   -12.38%    
IOVA   -7.47%    
• View Complete Report
   



Business Update

In a landscape where innovation competes fiercely with financial stability, Kiromic BioPharma, Inc. (OTCQB ...

Published Tue, Oct 8 2024 1:56 PM UTC

Harnessing Innovation: Kiromic BioPharma?s Deltacel Trial Shows Promise Amid Financial Struggles'In a landscape where innovation competes fiercely with financial stability, Kiromic BioPharma, Inc. (OTCQB: KRBP) is making waves with its Deltacel-01 Phase 1 clinical trial. The study is evaluating Deltacel (KB-GDT-01), a pioneering allogeneic, off-the-shelf Gamma Delta T-cell (...

Business Update

Hope for Lung Cancer Patients Kiromic BioPharmas Deltacel-01 Shows Promise in Latest Clinical Trial Resul...

Published Tue, Oct 1 2024 2:47 PM UTC

In an exciting development for oncology and immunotherapy, Kiromic BioPharma, Inc. (OTCQB: KRBP) announced favorable updates regarding its Deltacel-01 clinical trial, which is assessing the safety and efficacy of Deltacel (KB-GDT-01). This innovative allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy targets patients suffering from stage 4 metastatic non-small cell l...

Business Update

Kiromic BioPharma Enhances Deltacel-01 Cancer Trial by Partnering with University of Arizona Cancer Center, Pio...

Published Fri, Sep 20 2024 12:47 AM UTC

Houston, TX' - In a significant move to advance cancer therapy, Kiromic BioPharma, Inc. (OTCQB: KRBP) has announced the activation of the University of Arizona Cancer Center (UACC) as the fifth clinical trial site for the ongoing Phase 1 Deltacel-01 trial. This trial focuses on the evaluation of Deltacel (KB-GDT-01), an allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) the...

Business Update

Pioneering Gamma Delta T-Cell Therapy Unanimous SMC Endorsement Propels Deltacel-01 Clinical Trial to Exp...

Published Thu, Sep 19 2024 2:47 PM UTC

CSIMarket.com ''Abstract'Kiromic BioPharma, Inc. recently received a unanimous recommendation from their Safety Monitoring Committee (SMC) to progress the Deltacel-01 clinical trial to its expansion phase. The study focuses on the therapeutic efficacy and safety of Deltacel (KB-GDT-01), an allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy, in patients with stage 4 ...

Business Update

Kiromic BioPharmas Deltacel A Promising Leap in the Fight Against Metastatic Lung Cancer with FDA Fast Track Designa...

Published Wed, Aug 14 2024 12:47 PM UTC

Kiromic BioPharma's Deltacel: A Promising Leap in the Fight Against Metastatic Lung Cancer with FDA Fast Track Designation'In a significant advancement for oncology, Kiromic BioPharma, Inc. (OTCQB: KRBP) has announced that its innovative therapy, Deltacel (KB-GDT-01), has received FDA Fast Track designation. This designation is a critical milestone in the development of Delt...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com